{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:52Z","timestamp":1792783432182,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institutes of Health\/National Cancer Institute","award":["R01CA258994-03"],"award-info":[{"award-number":["R01CA258994-03"]}]},{"name":"Indiana University Comprehensive Cancer Center Disparity Pilot Grant","award":["Indiana University Comprehensive Cancer Center Disparity Pilot Grant"],"award-info":[{"award-number":["Indiana University Comprehensive Cancer Center Disparity Pilot Grant"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Racial and Ethnic Health Disparities"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Prostate cancer (PCa) is the second most diagnosed cancer in men, with Black and African American men (BAAM) experiencing higher incidence, more aggressive disease, and greater risk of biochemical recurrence (BCR) following radical prostatectomy (RP). This study investigated the use of\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11 PET\/CT to explore BCR patterns between racial groups at low prostate-specific antigen (PSA) levels (\u2264\u20092.0 ng\/mL) post-RP.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective study included 49 men with BCR post-RP: 17 BAAM and 32 White American men (WAM) who underwent\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11 PET\/CT at a National Cancer Institute-designated comprehensive cancer center between 2017 and 2021. Clinical and pathological data, including baseline PSA, PSA density, and PSA at scan, along with\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11 PET\/CT-derived parameters (detection rate, standardized uptake values [SUVmax and SUVmean], PSMA tumor volume [PSMA-TV], and total lesion PSMA [TL-PSMA]), were collected and compared between groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The overall detection rate was 57% (28\/49), with 47% (8\/17) in BAAM and 63% (20\/32) in WAM (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.39). BAAM had significantly higher baseline PSA levels (median: 13.80 versus 7.22 ng\/mL;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and PSA density (0.59 versus 0.16 ng\/mL\u00b2;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). At recurrence, PSA levels and lesion distribution were statistically similar. While WAM exhibited slightly higher SUVmax and SUVmean, BAAM demonstrated higher PSMA-TV, TL-PSMA, and whole-body volumetrics (wbPSMA-TV and wbTL-PSMA); although the differences were not statistically significant, they highlight areas for future exploration.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite BAAM presenting with more aggressive features at primary diagnosis, BAAM and WAM exhibited comparable PSMA-PET-derived tumor burden at recurrence. These findings will inform future studies with large, racially diverse populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40615-026-02993-1","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T14:17:52Z","timestamp":1778249872000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["68Ga-PSMA-11 PET\/CT for Detecting Biochemical Recurrence after Radical Prostatectomy in a Racially Diverse Population with Low PSA Levels"],"prefix":"10.1007","author":[{"given":"Ramotallah","family":"Jubril","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Ataya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Tann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clint","family":"Bahler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8120-1821","authenticated-orcid":false,"given":"Oluwaseyi","family":"Oderinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"2993_CR1","unstructured":"American Cancer Society. American Cancer Society. 2025 [cited 2024 Nov 15]. Cancer Statistics Center. Available from: https:\/\/cancerstatisticscenter.cancer.org\/"},{"key":"2993_CR2","unstructured":"CDC. United States Cancer Statistics. 2025 [cited 2025 May 11]. Prostate Cancer Incidence by Stage at Diagnosis. Available from: https:\/\/www.cdc.gov\/united-states-cancer-statistics\/publications\/prostate-cancer.html"},{"issue":"2","key":"2993_CR3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021;79(2):243\u201362.","journal-title":"Eur Urol"},{"issue":"9","key":"2993_CR4","doi-asserted-by":"publisher","first-page":"e2332900","DOI":"10.1001\/jamanetworkopen.2023.32900","volume":"6","author":"UG Falagario","year":"2023","unstructured":"Falagario UG, Abbadi A, Remmers S, Bj\u00f6rnebo L, Bogdanovic D, Martini A, et al. Biochemical Recurrence and Risk of Mortality Following Radiotherapy or Radical Prostatectomy. JAMA Netw Open. 2023;6(9):e2332900.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2993_CR5","doi-asserted-by":"publisher","first-page":"12589","DOI":"10.1038\/s41598-022-16395-w","volume":"12","author":"JF Su\u00e1rez","year":"2022","unstructured":"Su\u00e1rez JF, Zamora V, Garin O, Guti\u00e9rrez C, Pont \u00c0, Pardo Y, et al. Mortality and biochemical recurrence after surgery, brachytherapy, or external radiotherapy for localized prostate cancer: a 10-year follow-up cohort study. Sci Rep. 2022;12(1):12589.","journal-title":"Sci Rep"},{"issue":"11","key":"2993_CR6","doi-asserted-by":"publisher","first-page":"e70979","DOI":"10.1002\/cam4.70979","volume":"14","author":"C Cobbs","year":"2025","unstructured":"Cobbs C, Chesnut GT, Shafi AA. Understanding Racial Disparities in Prostate Cancer: A Multifaceted Approach. Cancer Med. 2025;14(11):e70979.","journal-title":"Cancer Med"},{"key":"2993_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.canlet.2022.01.028","volume":"531","author":"D Lowder","year":"2022","unstructured":"Lowder D, Rizwan K, McColl C, Paparella A, Ittmann M, Mitsiades N, et al. Racial disparities in prostate cancer: A complex interplay between socioeconomic inequities and genomics. Cancer Lett. 2022;531:71\u201382.","journal-title":"Cancer Lett"},{"key":"2993_CR8","unstructured":"SEER*Explorer Application [Internet]. [cited 2025 May 11]. Available from: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html?site=66&data_type=2&graph_type=10&compareBy=race&chk_race_9=9&chk_race_8=8&series=9&hdn_sex=2&age_range=1&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=2#resultsRegion0"},{"key":"2993_CR9","first-page":"214","volume":"6","author":"S Goswami","year":"2022","unstructured":"Goswami S, Sarkar C, Singh S, Singh AP, Chakroborty D. Racial differences in prostate tumor microenvironment: implications for disparate clinical outcomes and potential opportunities. Cancer Health Disparities. 2022;6:214.","journal-title":"Cancer Health Disparities"},{"issue":"9","key":"2993_CR10","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/nrc3341","volume":"12","author":"BE Henderson","year":"2012","unstructured":"Henderson BE, Lee NH, Seewaldt V, Shen H. The influence of race and ethnicity on the biology of cancer. Nat Rev Cancer. 2012;12(9):648\u201353.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2993_CR11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/JU.0000000000000193","volume":"202","author":"MI Echevarria","year":"2019","unstructured":"Echevarria MI, Awasthi S, Cheng CH, Berglund AE, Rounbehler RJ, Gerke TA, et al. African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome. J Urol. 2019;202(2):247\u201355.","journal-title":"J Urol"},{"issue":"12","key":"2993_CR12","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.3390\/cancers11121857","volume":"11","author":"J King Thomas","year":"2019","unstructured":"King Thomas J, Mir H, Kapur N, Singh S. Racial Differences in Immunological Landscape Modifiers Contributing to Disparity in Prostate Cancer. Cancers. 2019;11(12):1857.","journal-title":"Cancers"},{"issue":"6","key":"2993_CR13","doi-asserted-by":"publisher","first-page":"643","DOI":"10.7150\/ijbs.8974","volume":"10","author":"S Koochekpour","year":"2014","unstructured":"Koochekpour S, Buckles E, Shourideh M, Hu S, Chandra D, Zabaleta J, et al. Androgen Receptor Mutations and Polymorphisms in African American Prostate Cancer. Int J Biol Sci. 2014;10(6):643\u201351.","journal-title":"Int J Biol Sci"},{"issue":"2","key":"2993_CR14","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/S0090-4295(97)00617-1","volume":"51","author":"I Abdalla","year":"1998","unstructured":"Abdalla I, Ray P, Ray V, Vaida F, Vijayakumar S. Comparison of serum prostate-specific antigen levels and PSA density in african-american, white, and hispanic men without prostate cancer. Urology. 1998;51(2):300\u20135.","journal-title":"Urology"},{"issue":"6","key":"2993_CR15","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/j.urology.2014.08.039","volume":"84","author":"FA Faisal","year":"2014","unstructured":"Faisal FA, Sundi D, Cooper JL, Humphreys EB, Partin AW, Han M, et al. Racial Disparities in Oncologic Outcomes After Radical Prostatectomy: Long-term Follow-up. Urology. 2014;84(6):1434\u201341.","journal-title":"Urology"},{"issue":"4","key":"2993_CR16","first-page":"266","volume":"10","author":"K Gupta","year":"2022","unstructured":"Gupta K, Mehrotra V, Fu P, Scarberry K, MacLennan GT, Gupta S. Racial disparities in biochemical recurrence of prostate cancer. Am J Clin Exp Urol. 2022;10(4):266\u201370.","journal-title":"Am J Clin Exp Urol"},{"issue":"1","key":"2993_CR17","doi-asserted-by":"publisher","first-page":"20500","DOI":"10.1038\/s41598-022-24688-3","volume":"12","author":"M Haidar","year":"2022","unstructured":"Haidar M, Abi-Ghanem AS, Moukaddam H, Jebai ME, Al Zakleet S, Al Rayess S, et al. 68Ga-PSMA PET\/CT in early relapsed prostate cancer patients after radical therapy. Sci Rep. 2022;12(1):20500.","journal-title":"Sci Rep"},{"key":"2993_CR18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2147\/CMAR.S402241","volume":"15","author":"B Lian","year":"2023","unstructured":"Lian B, Qu M, Zhang W, Dong Z, Chen H, Jia Z, et al. Establishment and Validation of a Novel Prediction Model for Early Natural Biochemical Recurrence After Radical Prostatectomy Based on Post-Operative PSA at Sixth Week. Cancer Manag Res. 2023;15:377\u201385.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"2993_CR19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/us9.0000000000000002","volume":"35","author":"KS Patel","year":"2024","unstructured":"Patel KS, Singh T, Raghuvanshi K, Sonar S, Chaudhari R. A comparison study of 68gallium-prostate-specific membrane antigen positron emission tomography-computed tomography and multiparametric magnetic resonance imaging for locoregional staging of prostate cancer. Urol Sci. 2024;35(1):36.","journal-title":"Urol Sci"},{"issue":"11","key":"2993_CR20","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.2967\/jnumed.116.173492","volume":"57","author":"I Rauscher","year":"2016","unstructured":"Rauscher I, Maurer T, Beer AJ, Graner FP, Haller B, Weirich G, et al. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy. J Nucl Med. 2016;57(11):1713\u20139.","journal-title":"J Nucl Med"},{"key":"2993_CR21","doi-asserted-by":"publisher","first-page":"1079808","DOI":"10.3389\/fonc.2023.1079808","volume":"13","author":"B Detti","year":"2023","unstructured":"Detti B, Carnevale MG, Lucidi S, Burchini L, Caini S, Orsatti C, et al. Choline PET\/CT in recurrent prostate cancer. Front Oncol. 2023;13:1079808.","journal-title":"Front Oncol"},{"issue":"5","key":"2993_CR22","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1515\/cclm-2013-0675","volume":"52","author":"G Treglia","year":"2014","unstructured":"Treglia G, Ceriani L, Sadeghi R, Giovacchini G, Giovanella L. Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET\/CT in restaging prostate cancer patients: a meta-analysis. Clin Chem Lab Med. 2014;52(5):725\u201333.","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"2993_CR23","first-page":"127","volume":"9","author":"G Treglia","year":"2019","unstructured":"Treglia G, Pereira Mestre R, Ferrari M, Bosetti DG, Pascale M, Oikonomou E, et al. Radiolabelled choline versus PSMA PET\/CT in prostate cancer restaging: a meta-analysis. Am J Nucl Med Mol Imaging. 2019;9(2):127\u201339.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"1","key":"2993_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","volume":"41","author":"A Afshar-Oromieh","year":"2014","unstructured":"Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):11\u201320.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2993_CR25","doi-asserted-by":"publisher","first-page":"175628721881579","DOI":"10.1177\/1756287218815793","volume":"11","author":"M Moghul","year":"2019","unstructured":"Moghul M, Somani B, Lane T, Vasdev N, Chaplin B, Peedell C, et al. Detection rates of recurrent prostate cancer: 68Gallium (Ga)-labelled prostate-specific membrane antigen versus choline PET\/CT scans. A systematic review. Ther Adv Urol. 2019;11:1756287218815793.","journal-title":"Ther Adv Urol"},{"key":"2993_CR26","doi-asserted-by":"publisher","unstructured":"Yan L, Zhang Z, Wang T, Yuan L, Sun X, Su P. Application of targeted diagnosis of PSMA in the modality shift of prostate cancer diagnosis: a review. Front Oncol [Internet]. 2023 Sep 1 [cited 2024 Oct 26];13. Available from: https:\/\/www.frontiersin.org\/journals\/oncology\/articles\/https:\/\/doi.org\/10.3389\/fonc.2023.1179595\/full","DOI":"10.3389\/fonc.2023.1179595\/full"},{"issue":"11","key":"2993_CR27","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3390\/biomedicines8110511","volume":"8","author":"J Brumberg","year":"2020","unstructured":"Brumberg J, Beckl M, Dierks A, Schirbel A, Krebs M, Buck A, et al. Detection Rate of 68Ga-PSMA Ligand PET\/CT in Patients with Recurrent Prostate Cancer and Androgen Deprivation Therapy. Biomedicines. 2020;8(11):511.","journal-title":"Biomedicines"},{"issue":"11","key":"2993_CR28","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1007\/s00259-018-4042-z","volume":"45","author":"C Schmidkonz","year":"2018","unstructured":"Schmidkonz C, Cordes M, Schmidt D, B\u00e4uerle T, Goetz TI, Beck M, et al. 68Ga-PSMA-11 PET\/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45(11):1862\u201372.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2993_CR29","unstructured":"Dittrich RP, De Jesus O. Gallium Scan. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 May 14]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK567748\/"},{"key":"2993_CR30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.apradiso.2012.06.034","volume":"76","author":"A Sanchez-Crespo","year":"2013","unstructured":"Sanchez-Crespo A. Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography. Appl Radiat Isot. 2013;76:55\u201362.","journal-title":"Appl Radiat Isot"},{"issue":"4","key":"2993_CR31","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1021\/bc200279b","volume":"23","author":"M Eder","year":"2012","unstructured":"Eder M, Sch\u00e4fer M, Bauder-W\u00fcst U, Hull WE, W\u00e4ngler C, Mier W, et al. 68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging. Bioconjug Chem. 2012;23(4):688\u201397.","journal-title":"Bioconjug Chem"},{"key":"2993_CR32","doi-asserted-by":"publisher","unstructured":"Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D\u2019Amico AV, Dmochowski RR et al. Variation in the Definition of Biochemical Recurrence in Patients Treated for Localized Prostate Cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes. J Urol [Internet]. 2007 Feb [cited 2024 Oct 10]; Available from: https:\/\/www.auajournals.org\/doi\/https:\/\/doi.org\/10.1016\/j.juro.2006.10.097","DOI":"10.1016\/j.juro.2006.10.097"},{"issue":"2","key":"2993_CR33","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","volume":"65","author":"A Heidenreich","year":"2014","unstructured":"Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. Eur Urol. 2014;65(2):467\u201379.","journal-title":"Eur Urol"},{"key":"2993_CR34","doi-asserted-by":"crossref","unstructured":"Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016;40(2):244\u201352.","DOI":"10.1097\/PAS.0000000000000530"},{"issue":"12","key":"2993_CR35","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.2967\/jnumed.117.193581","volume":"58","author":"S Schmuck","year":"2017","unstructured":"Schmuck S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, Wester HJ, et al. Initial Experience with Volumetric 68Ga-PSMA I&T PET\/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer. J Nucl Med. 2017;58(12):1962\u20138.","journal-title":"J Nucl Med"},{"issue":"2","key":"2993_CR36","doi-asserted-by":"publisher","first-page":"240","DOI":"10.2967\/jnumed.120.261886","volume":"63","author":"JJ Cerci","year":"2022","unstructured":"Cerci JJ, Fanti S, Lobato EE, Kunikowska J, Alonso O, Medina S, et al. Diagnostic Performance and Clinical Impact of 68Ga-PSMA-11 PET\/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study). J Nucl Med. 2022;63(2):240\u20137.","journal-title":"J Nucl Med"},{"issue":"6","key":"2993_CR37","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, et al. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019;5(6):856\u201363.","journal-title":"JAMA Oncol"},{"issue":"2","key":"2993_CR38","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/JU.0000000000000198","volume":"202","author":"N Tan","year":"2019","unstructured":"Tan N, Bavadian N, Calais J, Oyoyo U, Kim J, Turkbey IB, et al. Imaging of Prostate Specific Membrane Antigen Targeted Radiotracers for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis. J Urol. 2019;202(2):231\u201340.","journal-title":"J Urol"},{"issue":"9","key":"2993_CR39","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","volume":"20","author":"J Calais","year":"2019","unstructured":"Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019;20(9):1286\u201394.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2993_CR40","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s11307-025-02020-5","volume":"27","author":"M Beheshti","year":"2025","unstructured":"Beheshti M, Shahbazi-Akbari M, Hacker M, Loidl W, Langsteger W. [68Ga]Ga-PSMA-11 PET\/CT and [18F]Fluorocholine PET\/CT in Assessment and Clinical Decision Making of Recurrent Prostate Cancer: A Prospective Crossover Trial. Mol Imaging Biol. 2025;27(4):597\u2013605.","journal-title":"Mol Imaging Biol"},{"issue":"4","key":"2993_CR41","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"M Perera","year":"2020","unstructured":"Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. Eur Urol. 2020;77(4):403\u201317.","journal-title":"Eur Urol"},{"key":"2993_CR42","doi-asserted-by":"crossref","unstructured":"Eastham JA, May RA, Whatley T, Crow A, Venable DD, Sartor O. Clinical Characteristics and Biopsy Specimen Features in African-American and White Men Without Prostate Cancer. J Natl Cancer Inst. 1998;90(10).","DOI":"10.1093\/jnci\/90.10.756"},{"issue":"2","key":"2993_CR43","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/jnci\/89.2.134","volume":"89","author":"RJ Henderson","year":"1997","unstructured":"Henderson RJ, Eastham JA, Daniel JC, Whatley T, Mata J, Venable D, et al. Prostate-Specific Antigen (PSA) and PSA Density: Racial Differences in Men Without Prostate Cancer. JNCI J Natl Cancer Inst. 1997;89(2):134\u20138.","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"3","key":"2993_CR44","first-page":"190","volume":"19","author":"JT Rathbun","year":"2017","unstructured":"Rathbun JT, Schroeder TM, Eberhardt SC. High postprostatectomy prostate-specific antigen level prior to salvage radiation therapy is not always a bad sign. Rev Urol. 2017;19(3):190\u20134.","journal-title":"Rev Urol"},{"issue":"5","key":"2993_CR45","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.3390\/jcm9051390","volume":"9","author":"PE Hartrampf","year":"2020","unstructured":"Hartrampf PE, Heinrich M, Seitz AK, Brumberg J, Sokolakis I, Kalogirou C, et al. Metabolic Tumour Volume from PSMA PET\/CT Scans of Prostate Cancer Patients during Chemotherapy\u2014Do Different Software Solutions Deliver Comparable Results? J Clin Med. 2020;9(5):1390.","journal-title":"J Clin Med"},{"issue":"2","key":"2993_CR46","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00259-020-04981-x","volume":"48","author":"A Santos","year":"2021","unstructured":"Santos A, Mattiolli A, Carvalheira JB, Ferreira U, Camacho M, Silva C, et al. PSMA whole-body tumor burden in primary staging and biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48(2):493\u2013500.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2993_CR47","doi-asserted-by":"publisher","first-page":"1025930","DOI":"10.3389\/fonc.2022.1025930","volume":"12","author":"S Dong","year":"2022","unstructured":"Dong S, Li Y, Chen J, Li Y, Yang P, Li J. 18F-PSMA-1007 PET\/CT-derived semi-quantitative parameters for risk stratification of newly diagnosed prostate cancer. Front Oncol. 2022;12:1025930.","journal-title":"Front Oncol"},{"issue":"2","key":"2993_CR48","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/MNM.0000000000000791","volume":"39","author":"T Lengana","year":"2018","unstructured":"Lengana T, van de Wiele C, Lawal I, Maes A, Ebenhan T, Boshomane T, et al. 68Ga-PSMA-HBED-CC PET\/CT imaging in Black versus White South African patients with prostate carcinoma presenting with a low volume, androgen-dependent biochemical recurrence: a prospective study. Nucl Med Commun. 2018;39(2):179\u201385.","journal-title":"Nucl Med Commun"},{"issue":"4","key":"2993_CR49","doi-asserted-by":"publisher","first-page":"882","DOI":"10.3390\/biomedicines10040882","volume":"10","author":"LC Maserumule","year":"2022","unstructured":"Maserumule LC, Mokoala KMG, van de Wiele C, Popoola G, Hlongwa KN, Ndlovu H, et al. 68Ga-PSMA-11 PET\/CT Initial Staging in Black and White South African Males with ISUP Grade Group 1 and 2 Prostate Adenocarcinoma. Biomedicines. 2022;10(4):882.","journal-title":"Biomedicines"},{"issue":"2","key":"2993_CR50","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s00259-017-3852-8","volume":"45","author":"M Sathekge","year":"2018","unstructured":"Sathekge M, Lengana T, Maes A, Vorster M, Zeevaart J, Lawal I, et al. 68Ga-PSMA-11 PET\/CT in primary staging of prostate carcinoma: preliminary results on differences between black and white South-Africans. Eur J Nucl Med Mol Imaging. 2018;45(2):226\u201334.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Journal of Racial and Ethnic Health Disparities"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40615-026-02993-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40615-026-02993-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40615-026-02993-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T09:29:02Z","timestamp":1778578142000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40615-026-02993-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":50,"alternative-id":["2993"],"URL":"https:\/\/doi.org\/10.1007\/s40615-026-02993-1","relation":{},"ISSN":["2197-3792","2196-8837"],"issn-type":[{"value":"2197-3792","type":"print"},{"value":"2196-8837","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Indiana University Hospital (IRB No. 11330), and all study protocols were performed in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"Informed consent was waived due to the retrospective design of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Dr. Clint Bahler is a paid consultant for Telix Pharmaceuticals. No other disclosures werereported.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}